uploads/2018/06/syringe-1884779_1280.jpg

How Much Upside Analysts See In Novavax Stock

By

Updated

Company overview

Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing recombinant nanoparticle vaccines and adjuvants to market. These vaccine candidates are genetically engineered, three-dimensional nanostructures. Its lead vaccine candidates target respiratory syncytial virus and influenza.

Analysts’ recommendations

Of the eight analysts covering Novavax, four have recommended “buy” or a higher rating, three have recommended “hold,” and one has recommended “sell.” Their mean rating for the stock is 2.4, and their target price is $3.93, implying a 144% upside based on its June 13 closing price of $1.61.

Peer ratings

Of the 20 analysts covering Merck (MRK), 15 have recommended “buy” or a higher rating, and five have recommended “hold.” Their mean rating for the stock is 2, and their target price is $69.02.

Of the nine analysts covering Arena Pharmaceuticals (ARNA), eight have recommended “buy” or a higher rating, and one has recommended “hold.” Their mean rating for the stock is 1.8, and their target price is $61.89.

Of the 21 analysts covering Bristol-Myers Squibb (BMY), seven have recommended “buy” or a higher rating, 12 have recommended “hold,” and two have recommended “sell.” Their mean rating for the stock is 2.6, and their target price is $57.58. In the next part of this series, we’ll look at Novavax’s research pipeline.

More From Market Realist